Crinetics Pharmaceuticals Q4 EPS $(0.90) Misses $(0.86) Estimate
Portfolio Pulse from saritha@benzinga.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported a Q4 EPS loss of $(0.90), missing the consensus estimate of $(0.86) by 4.65%. This represents a 7.14% increase in losses compared to the same period last year.
February 28, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Crinetics Pharmaceuticals reported a larger than expected Q4 loss, missing analyst estimates.
Missing the earnings estimate and reporting a larger loss compared to the previous year is generally seen as a negative indicator for a company's financial health and can lead to a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100